Shorter radiation matched standard treatment after breast cancer mastectomy

In a trial of 898 women with breast cancer who had mastectomy and breast reconstruction, a three-week radiation course had similar reconstruction complication rates to a five-week course: 12.3% versus 10.2% at two years.

What this means. A large, final-stage trial in breast cancer. This is the kind of result regulators use when deciding whether to approve a treatment.

CAR T-cell therapy shows no delayed toxicity in recurrent glioblastoma

In a phase I trial, 18 people with recurrent glioblastoma received one dose of CAR T-cell therapy. Median survival was 12.0 months, and researchers found no delayed toxicities, though all patients had acute toxicities.

What this means. An early trial in brain cancer, mainly testing safety and dose. Any new treatment here is years away from routine use.

Cancer actionability framework revised for precision oncology

The ESCAT framework was revised as precision oncology evolved, with new therapy approvals, real-world evidence and recognition of biomarkers linked to treatment resistance.

What this means. Based on data or samples from people with cancer. It is not a treatment trial.

Federal policy changes disrupt cancer disparities research, survey finds

In an online survey, 154 people working in cancer disparities research reported the effects of federal policy changes. Nearly 93% said the changes had adversely affected their work.

“He pointed to the establishment of the AACR Minority Scholar in Cancer Research Award in 1985 and increased representation of historically underrepresented groups within major oncology organizations as examples of how sustained efforts to support workforce development have helped transform the field. “We have made substantial progress,” Winn said.”

What this means. Based on data or samples from people with cancer. It is not a treatment trial.

Remote expert reviews changed care in cancer cases

A review of 1,417 cancer cases found treating oncologists adopted expert recommendations in more than half of eligible cases. Hematologic malignancies made up 28% of cases, and the reviews were linked to cost savings.

“Remote expert review of oncology cases may help to address and improve gaps in evidence-based cancer care, while also providing measurable cost savings, according to findings presented in a poster at the 2026 ASCO Quality Care Symposium ( Abstract 700 ). “ Last year at ASCO's Quality Care Symposium , we showed that remote expert recommendations can meaningfully bridge socioeconomic and geographic barriers in cancer care, particularly for patients in nonurban communities.”

What this means. Based on data or samples from people with cancer. It is not a treatment trial.